Market Report Source

Overview

The Latin American Market Outlook to 2010 is a new management report which provides comprehensive coverage of the major cardiovascular markets in the Latin American region. This report provides detailed analysis of market trends, epidemiology, current leading brands of treatment, product sales forecast and future market leaders over the period 2005-2010 in ten markets: Brazil, Mexico, Argentina, Puerto Rico, Chile, Venezuela, Colombia, Ecuador, Peru, Uruguay. The Latin American cardiovascular market exhibits significant differences from both the global market and from other emerging cardiovascular markets. The high levels of public and private healthcare spending, means opportunities for price-competitive drugs, generics and modern branded drugs. Such opportunities differ vastly across this geographic region and indications, a reality that marketers must be aware of in order to achieve success. This report will allow you to identify the right combination of products in your portfolio to achieve corporate success in a market that is significantly differentiated from all other regional cardiovascular markets .Reading this report will provide you with the tools to identify market trends in developed and emerging Latin American countries, assess the dominant forces driving market growth and develop potential growth and diversification opportunities in this region over the period 2005-2010.

Table of Contents

Table of Contents

The Latin American Cardiovascular Market Outlook to

Patient potential

Regional healthcare and licensing trends

Regional market analysis

Key players in the Latin American cardiovascular market

Chapter 1 Patient potential

Summary

Introduction

Disease description

Defining patient potential

Limitations of cardiovascular epidemiology data

Cardiovascular risk factors

Hypertension

Prevalence

Factors driving prevalence

Diagnosis, awareness and treatment of hypertension

Forecast prevalence of hypertension in Latin America

Dyslipidemia

Prevalence

Factors driving prevalence

Forecast prevalence of hypercholesterolemia in Latin America

Diabetes

Epidemiology of diabetes in Latin America

Prevalence

Forecast prevalence of diabetes

Cardiovascular disease

Prevalence

Acute thrombotic events

Acute coronary syndromes

Venous thromboembolism

Stroke

iv

Chapter 2 Regional healthcare and licensing

trends

Summary

Introduction

Regional healthcare expenditure

Healthcare reforms

Healthcare financing

The external environment

Licensing analysis

Chapter 3 Regional market analysis

Summary

Introduction

Market breakdown by therapy area

Leading products

Market breakdown by country

Anti-hypertensives

Introduction

Analysis of the top 10 anti-hypertensives

Hypertension class sales by country, 2004

Market analysis by drug class

ACE inhibitors

Angiotensin receptor blockers

Beta blockers

Diuretics

Calcium channel blockers

Alpha-blocker/centrally acting hypertensives

Anti-hypertensives sales forecasts

Anti-dyslipidemics

Introduction

Analysis of the top 10 anti-dyslipidemics

Regional dynamics

Market analysis by drug class

Statins

Fibrates

Other anti-dyslipidemics

Anti-dyslipidemics sales forecasts

Anti-thrombotics

Introduction

Analysis of the top 10 anti-thrombotics

Regional dynamics

Market analysis by drug class

v

Anti-platelets

Heparins/low molecular weight heparins

Vitamin K antagonists

Fibrinolytics

Anti-thrombotics sales forecasts

Cardiac therapies

Introduction

Analysis of the top 10 cardiac therapies

Market analysis by drug class

Nitrites/nitrates

Anti-arrhythmics

Other cardiac therapy drugs

Cardiac therapies sales forecasts

Chapter 4 Key players in the Latin American

cardiovascular market

Summary

Latin American market shares

Pfizer

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Sanofi-Aventis

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Merck & Co.

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Novartis

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

AstraZeneca

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Bristol-Myers Squibb

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Bayer

Marketed products

R&D compounds

vi

Cardiovascular portfolio sales forecasts

Boehringer Ingelheim

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Chapter 5 Appendix

IMS sales data

Glossary

Index

List of Figures

Figure 1.1: Relationship between cardiovascular disease and risk factors

Figure 1.2: Risk factors associated with hypertension

Figure 1.3: Awareness and treatment rates in a selection of Latin American countries, 2001

Figure 1.4: Prevalence of obesity in Latin America

Figure 2.5: External analysis of Latin American markets

Figure 3.6: Competitive dynamics in the Latin American cardiovascular market, 2003–04

Figure 3.7: Leading brand dynamics in the Latin American cardiovascular market, 2003–04

Figure 3.8: Competitive dynamics in the Latin American anti-hypertensives market by drug class,

2003–04

Figure 3.9: Competitive dynamics of the top ten anti-hypertensives by drug class, 2003–04

Figure 3.10: Competitive dynamics in the Latin American anti-dyslipidemics market, 2003–04

Figure 3.11: Competitive dynamics in the Latin American anti-dyslipidemics market by leading

brands, 2003–04

Figure 3.12: Competitive dynamics in the Latin American anti-thrombotics market, 2003–04

Figure 3.13: Competitive dynamics in the Latin American anti-thrombotics market by leading

brands, 2003–04

Figure 3.14: Competitive dynamics in the Latin American cardiac therapy market by drug class,

2003–04

Figure 3.15: Competitive dynamics of the top Latin American cardiac therapies by drug class,

Figure 4.16: Market share of key players in the Latin American cardiovascular market, 2000 and

2004

vii

List of Tables

Table 1.1: Estimated prevalence of hypertension in the Latin American markets, 2004

Table 1.2: Estimated prevalence of hypertension in the Latin American markets, 2005–10

Table 1.3: Clinical guidelines for adult patients at borderline and high risk of cardiovascular

disease by serum levels of lipids

Table 1.4: Estimated prevalence of hypercholesterolemia in Latin American markets, 2004

Table 1.5: Estimated prevalence of diabetes in Latin America, 2004

Table 1.6: Estimated prevalence of diabetes in Latin America, 2005–10

Table 1.7: Estimated prevalence of major cardiovascular diseases in the Latin American market,

2004

Table 1.8: Estimated incidence of ACS in the Latin American market, 2004

Table 1.9: Estimated incidence of VTE in the Latin American market, 2004

Table 1.10: Prevalence of stroke in ten Latin American markets, 2004

Table 2.11: Recent statistics on healthcare expenditure in the Latin American markets, 2002

Table 2.12: Public and private financing in the Latin American markets, 2002

Table 2.13: Sales of types of cardiovascular brands in ten Latin American markets, 2004

Table 3.14: Breakdown of Latin American cardiovascular market by major therapeutic area, 2000–

04

Table 3.15: Top 10 selling cardiovascular products in the Latin American market, 2004

Table 3.16: Cardiovascular sales across twelve Eastern European markets, 2004

Table 3.17: Breakdown of Latin American anti-hypertensives market by drug class, 2000–04

Table 3.18: Breakdown of the Latin American anti-hypertensives market by leading brands, 2003–

04

Table 3.19: Market share of the leading classes of anti-hypertension drugs in the Latin American

market, 2004

Table 3.20: Market share of the ACE inhibitors/ARBs category in the Latin American market,

2004

Table 3.21: Breakdown of the ACE inhibitor market in the Latin American countries by leading

brands, 2003–04

Table 3.22: Breakdown of the global ARB market by leading brands, 2003–04

Table 3.23: Market share of the beta-blocker class in the Latin American market, 2004

Table 3.24: Breakdown of the Latin American beta-blocker market by leading brands, 2003–04

Table 3.25: Market share of the diuretics class in the Latin American market, 2004

Table 3.26: Breakdown of the diuretics market in Latin America by leading brands, 2003–04

Table 3.27: Market share of the CCB class in the Latin American market, 2004

Table 3.28: Breakdown of the CCB market in Latin American countries by leading brands, 2003–

04

Table 3.29: Market share of centrally acting/alpha blockers classes in the Latin American market,

2004

Table 3.30: Breakdown of the alpha-blockers/centrally acting drugs market in Latin American

countries by leading brands, 2003–04

Table 3.31: Sales forecasts for hypertension drug classes in the Latin American market, 2004–

Table 3.32: Breakdown of the Latin American anti-dyslipidemic market by drug class, 2000–04

Table 3.33: Breakdown of the Latin American anti-dyslipidemics market by leading brands, 2003–04

Table 3.34: Market share of dyslipidemia class of drugs in the Latin American market, 2004

viii

Table 3.35: Sales forecasts for dyslipidemia drug classes in the Latin American market, 2004–

Table 3.36: Breakdown of the Latin American anti-thrombotics market by drug class, 2000–04

Table 3.37: Breakdown of the Latin American anti-thrombotics market by leading brands, 2004–

Table 3.38: Market share of anti-thrombotics in the Latin American market, 2004

Table 3.39: Sales forecasts for thrombosis drug classes in the Latin American market, 2004–10

Table 3.40: Breakdown of Latin American cardiac therapy market by drug class, 2000–04

Table 3.41: Breakdown of the Latin American cardiac therapy market by leading brands, 2004

Table 3.42: Sales forecasts for cardiac therapies drug classes in the Latin American market, 2004–10

Table 4.43: Key players in the Latin American cardiovascular market, 2000–2004

Table 4.44: Pfizer’s marketed cardiovascular portfolio, 2004

Table 4.45: Pfizer’s cardiovascular R&D pipeline, 2005

Table 4.46: Forecast sales for Pfizer’s Latin American cardiovascular portfolio, 2004–10

Table 4.47: Sanofi-Aventis’ marketed cardiovascular portfolio, 2004

Table 4.48: Sanofi-Aventis’ cardiovascular R&D pipeline, 2005

Table 4.49: Forecast sales for Sanofi-Aventis’ cardiovascular portfolio, 2004–10

Table 4.50: Merck’s marketed cardiovascular portfolio, 2004

Table 4.51: Merck’s cardiovascular R&D pipeline, 2005

Table 4.52: Forecast sales for Merck’s cardiovascular portfolio, 2004–10

Table 4.53: Novartis’ marketed cardiovascular portfolio, 2004

Table 4.54: Novartis’ cardiovascular R&D pipeline, 2005

Table 4.55: Forecast sales for Novartis’ cardiovascular portfolio, 2004–10

Table 4.56: AstraZeneca’s marketed cardiovascular portfolio, 2004

Table 4.57: AstraZeneca’s cardiovascular R&D pipeline, 2005

Table 4.58: Forecast sales for AstraZeneca’s cardiovascular portfolio, 2004–10

Table 4.59: BMS’ marketed cardiovascular portfolio, 2004

Table 4.60: Bristol-Myers Squibb’s cardiovascular R&D pipeline, 2005

Table 4.61: Forecast sales for BMS’ cardiovascular portfolio, 2004–10

Table 4.62: Bayer’s marketed cardiovascular portfolio, 2004

Table 4.63: Bayer’s cardiovascular R&D pipeline, 2005

Table 4.64: Forecast sales for Bayer’s cardiovascular portfolio, 2004–10

Table 4.65: Boehringer Ingelheim’s marketed cardiovascular portfolio, 2004

Table 4.66: Boehringer Ingelheim’s cardiovascular R&D pipeline, 2005

Table 4.67: Forecast sales for BI’s cardiovascular portfolio, 2004–10 145